黄芪多糖在Her-2阳性乳腺癌患者化疗中增效减毒的作用及其对血清Her-2-ECD、TAP和疗效的影响OA

Objective:To investigate the effect of Astragalus Polysaccharide on enhancing efficacy and reducing toxicity during chemotherapy in patients with human epidermal growth factor receptor-2(Her-2)positive breast cancer and influence on serum human epidermal growth factor receptor-2-extracellular domain(Her-2-ECD),tumor abnormal protein(TAP)and therapeutic efficacy.Method:A total of 90 patients with Her-2 positive breast cancer admitted to Xinyu Beihu Hospital from January 2020 to June 2023 were selected as the study objects,and the patients were randomly divided into control group and observation group,with 45 cases in each group.Both groups were treated with TCbHP(Docetaxel+Carboplatin+Trastuzumab+Pertuzumab)regimen.The observation group was given Astragalus Polysaccharide for Injection treatment on this basis.The traditional Chinese medicine syndrome score,serum Her-2-ECD,TAP levels,immune function(CD4+,CD8+),white blood cell(WBC)levels,functional assessment of cancer therapy-breast(FACT-B)score before and after treatment,efficacy and incidence of adverse reactions between the two groups were compared.Result:Before treatment,there were no significant differences in traditional Chinese medicine syndrome scores,Her-2-ECD,TAP,CD4+,CD8+,WBC and FACT-B scores between the two groups(P>0.05).After treatment,the traditional Chinese medicine symptoms scores,Her-2-ECD,TAP,CD8+,FACT-B scores and the incidence of adverse reactions in the observation group were lower than those in the control group,and CD4+,WBC and total effective rate were higher than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Astragalus Polysaccharide can improve the chemotherapy effect of Her-2 positive breast cancer patients,reduce the toxic reaction caused by chemotherapy,and improve the quality of life of patients.